Floatz logo

Ipatasertib

Triple-Negative Breast Carcinoma

MedSIRSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
65/ 100

Competitive context

427 Active assets in the Triple-Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Ipatasertib is also rated in:

estrogen-receptor positive breast cancerActive
BB
Indicative · Phase 2
64 / 100
View asset →
breast cancerActive
B
Indicative · Phase 3
60 / 100
View asset →
metastatic prostate carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →